Inhibiting tumor necrosis factor-α before amyloidosis prevent synaptic deficits in an Alzheimer's disease model

被引:58
|
作者
Cavanagh, Chelsea [1 ,2 ]
Tse, Yiu Chung [1 ]
Huy-Binh Nguyen [1 ,2 ]
Krantic, Slavica [3 ,4 ,5 ,6 ]
Breitner, John C. S. [1 ,7 ,8 ]
Quirion, Remi [1 ,2 ,8 ]
Tak Pan Wong [1 ,2 ,8 ]
机构
[1] Douglas Mental Hlth Univ Inst, 6875 LaSalle Blvd, Montreal, PQ H4H 1R3, Canada
[2] McGill Univ, Integrated Program Neurosci, Montreal, PQ, Canada
[3] UPMC Univ Paris 06, Sorbonne Univ, UMR S 1138, Ctr Rech Cordeliers, Paris, France
[4] Ctr Rech Cordeliers, INSERM, UMR S 1138, Paris, France
[5] Univ Paris 05, Sorbonne Paris Cite, UMR S 1138, Ctr Rech Cordeliers, Paris, France
[6] CNRS, ERL 8228, Ctr Rech Cordeliers, Paris, France
[7] Ctr Studies Prevent Alzheimers Dis, Montreal, PQ, Canada
[8] McGill Univ, Dept Psychiat, Montreal, PQ, Canada
基金
加拿大健康研究院;
关键词
Prevention; Synaptic plasticity; Hippocampus; Prodromal; XPro1595; Hyperexcitability; LONG-TERM POTENTIATION; MILD COGNITIVE IMPAIRMENT; TGCRND8 MOUSE MODEL; DOUBLE-EDGED-SWORD; TNF-ALPHA; TRANSGENIC MICE; AMPA-RECEPTOR; NEURODEGENERATIVE DISEASE; PRECURSOR PROTEIN; MEMORY DEFICITS;
D O I
10.1016/j.neurobiolaging.2016.07.009
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Deficits in synaptic structure and function are likely to underlie cognitive impairments in Alzheimer's disease. While synaptic deficits are commonly found in animal models of amyloidosis, it is unclear how amyloid pathology may impair synaptic functions. In some amyloid mouse models of Alzheimer's disease, however, synaptic deficits are preceded by hyperexcitability of glutamate synapses. In the amyloid transgenic mouse model TgCRND8, we therefore investigated whether early enhancement of glutamatergic transmission was responsible for development of later synaptic deficits. Hippocampi from 1-month-old TgCRND8 mice revealed increased basal transmission and plasticity of glutamate synapses that was related to increased levels of tumor necrosis factor alpha (TNF alpha). Treating these 1-month-old mice for 4 weeks with the TNFa inhibitor XPro1595 prevented synaptic deficits otherwise apparent at the age of 6 months. In this mouse model at least, reversing the hyperexcitability of glutamate synapses via TNFa blockade before the onset of amyloid plaque formation prevented later synaptic deficits. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 50 条
  • [21] Tumor Necrosis Factor and Alzheimer's Disease: A Cause and Consequence Relationship
    Sharma, Vivek
    Thakur, Vinay
    Singh, Shesh Nath
    Guleria, Rajender
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 22 (01): : 86 - 97
  • [22] Early intervention with a small molecule inhibitor for tumor nefosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease
    S Prasad Gabbita
    Minu K Srivastava
    Pirooz Eslami
    Ming F Johnson
    Naomi K Kobritz
    David Tweedie
    Nigel H Greig
    Frank P Zemlan
    Sherven P Sharma
    Marni E Harris-White
    Journal of Neuroinflammation, 9
  • [23] Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease
    Sack, MN
    PHARMACOLOGY & THERAPEUTICS, 2002, 94 (1-2) : 123 - 135
  • [24] Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia
    Elisabeth Tarkowski
    Kaj Blennow
    Anders Wallin
    Andrzej Tarkowski
    Journal of Clinical Immunology, 1999, 19 : 223 - 230
  • [25] Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia
    Tarkowski, E
    Blennow, K
    Wallin, A
    Tarkowski, A
    JOURNAL OF CLINICAL IMMUNOLOGY, 1999, 19 (04) : 223 - 230
  • [26] Microglial derived tumor necrosis factor-α drives Alzheimer's disease-related neuronal cell cycle events
    Bhaskar, Kiran
    Maphis, Nicole
    Xu, Guixiang
    Varvel, Nicholas H.
    Kokiko-Cochran, Olga N.
    Weick, Jason P.
    Staugaitis, Susan M.
    Cardona, Astrid
    Ransohoff, Richard M.
    Herrup, Karl
    Lamb, Bruce T.
    NEUROBIOLOGY OF DISEASE, 2014, 62 : 273 - 285
  • [27] Mycobacterial Disease Attributable to Tumor Necrosis Factor-α Blockers
    Wallis, Robert. S.
    CLINICAL INFECTIOUS DISEASES, 2008, 47 (12) : 1603 - 1605
  • [28] Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
    Jacobsen, JS
    Wu, CC
    Redwine, JM
    Comery, TA
    Arias, R
    Bowlby, M
    Martone, R
    Morrison, JH
    Pangalos, MN
    Reinhart, PH
    Bloom, FE
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (13) : 5161 - 5166
  • [29] Tumor necrosis factor-α promoter polymorphism is associated with the risk of Parkinson's disease
    Wu, Yih-Ru
    Feng, I-Hsin
    Lyu, Rong-Kuo
    Chang, Kuo-Hsuan
    Lin, Yu-Yun
    Chan, Huiling
    Hu, Fen-Ju
    Lee-Chen, Guey-Jen
    Chen, Chiung-Mei
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2007, 144B (03) : 300 - 304
  • [30] Comparison of specific adsorbents for tumor necrosis factor-α and therapeutic anti-tumor necrosis factor-α antibodies:: An in vitro sepsis model
    Schwanzer-Pfeiffer, D.
    Mitteregger, R.
    Rossmanith, E.
    Falkenhagen, D.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2006, 29 (12): : 1140 - 1147